Therapeutic Peptides: Complete 2026 Guide

What a therapeutic peptide actually is

A therapeutic peptide is a molecule made of roughly 2 to 50 amino acids, small enough to reach and bind a specific cell-surface receptor but structured enough to carry a defined biological signal. Because most peptides act on one receptor family, their side-effect profiles tend to track that one receptor's biology rather than spreading across unrelated organ systems the way many small-molecule drugs do.

Peptides sit between small molecules (aspirin, metformin, generally under 500 daltons, absorbed orally) and large proteins (insulin, growth hormone, generally requiring cold storage and injection). Most peptides are broken down by stomach acid, which is why the majority are given by subcutaneous or intramuscular injection rather than by mouth; oral semaglutide (Rybelsus) is a notable exception built around a permeation enhancer.

The core distinction that should drive every decision on this page is regulatory and evidentiary, not chemical. Semaglutide and tirzepatide are FDA-approved drugs studied in randomized trials with tens of thousands of participants and known dosing, contraindications, and monitoring requirements. Peptides such as BPC-157, TB-500, and most growth hormone secretagogue combinations are compounded, off-label, and supported mainly by animal studies or small early-phase human data, meaning the effect size, optimal dose, and long-term safety in humans have not been established. Treating those two categories as interchangeable "peptide therapy" is the single most common source of confusion for patients researching this topic.

GLP-1 and dual GIP/GLP-1 receptor agonists: the best-evidenced class

GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are the most clinically validated peptide-based drugs available, with FDA approval, multiple large randomized controlled trials, and (for semaglutide) cardiovascular outcomes data.

Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is a GLP-1 analogue modified with a fatty-acid side chain that binds albumin, extending its half-life to roughly a week and allowing once-weekly injections (or daily oral dosing for Rybelsus). In the pivotal STEP-1 obesity trial, semaglutide 2.4 mg weekly was associated with substantially greater weight loss than placebo at 68 weeks in adults with overweight or obesity; a separate cardiovascular outcomes trial in people with type 2 diabetes and established cardiovascular disease found a reduction in major adverse cardiovascular events versus placebo. The FDA approved semaglutide for chronic weight management (Wegovy) in 2021 and later expanded labeling to include cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease. Exact percentage effect sizes from these trials are widely reported in secondary sources; a clinician or medical reviewer should confirm the current, precise figures against the original trial publications before they are republished as fixed numbers, since pooled and per-dose results vary across analyses.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide activates both the GIP receptor and the GLP-1 receptor, a dual mechanism that appears to produce greater average weight loss than GLP-1 agonism alone in head-to-head-adjacent trial comparisons. The FDA approved tirzepatide for chronic weight management (Zepbound) in November 2023, following the SURMOUNT-1 obesity trial. As with semaglutide, the specific mean weight-loss percentages reported in secondary summaries should be checked against the primary trial report before being stated as a precise, unqualified figure in patient-facing material.

Comparing semaglutide and tirzepatide

Direct numeric head-to-head comparisons between the two drugs' weight-loss percentages should be sourced from a trial that randomized both drugs against each other, not from cross-trial comparison of separate placebo-controlled studies, which can be misleading due to differences in population and duration.

The guideline picture

Major diabetes and obesity guideline bodies, including the American Diabetes Association and the Endocrine Society, recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists as part of first-line pharmacotherapy for eligible adults with type 2 diabetes and overweight or obesity, and for chronic weight management more broadly when lifestyle intervention alone has not achieved goals. This is a guideline-level recommendation, not a description of any single patient's expected result, and the current wording should be checked against each society's most recent published standards before being quoted directly.

Growth hormone peptides: secretagogues and releasing factors

Growth hormone peptides do not supply growth hormone directly. They stimulate the pituitary to release more of its own GH, which matters for both safety (endogenous feedback loops remain partly intact) and legality (most are compounded, off-label products rather than approved drugs).

CJC-1295 and ipamorelin

CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. Ipamorelin is a selective agonist at the ghrelin/growth hormone secretagogue receptor. Combining them targets two separate pituitary GH-release pathways. Early-phase human data on CJC-1295 have reported dose-dependent increases in IGF-1, and ipamorelin is generally described as producing a GH pulse with less off-target cortisol or prolactin effect than older secretagogues such as GHRP-6. These are Phase I-level or small-study findings rather than large randomized trials with clinical outcome endpoints, and neither peptide has FDA approval for any indication. A commonly used compounded protocol involves subcutaneous bedtime dosing several days per week, but there is no FDA-approved dosing standard, and any specific regimen should come from a prescriber managing the patient directly, not from a general guide.

Sermorelin

Sermorelin, the first 29 amino acids of endogenous GHRH, previously had FDA approval for pediatric GH deficiency; that approval was withdrawn by the manufacturer in 2008, not for safety reasons. It is currently available through compounding pharmacies for off-label adult use. Human data on lean-mass or body-composition effects come from small trials, and effect sizes should be treated as preliminary until confirmed in the primary literature.

Tesamorelin (Egrifta SV)

Tesamorelin is the only GHRH analogue with current FDA approval, indicated specifically for HIV-associated lipodystrophy at 2 mg subcutaneous daily, based on randomized trial data showing reduction in visceral adipose tissue in that population. Off-label use in people without HIV for general visceral fat reduction is not supported by the same evidence base and should be discussed explicitly as an off-label extrapolation.

Tissue repair peptides: BPC-157 and TB-500

BPC-157 is a 15-amino-acid peptide derived from a gastric protective protein. TB-500 is a synthetic fragment of thymosin beta-4. Both are widely discussed in performance and recovery communities. As of this writing, neither has completed a Phase III human trial for musculoskeletal repair, and neither is FDA-approved for any indication.

BPC-157

Animal studies have reported pro-healing effects across models of tendon, gut, and nerve injury. Human data are limited to small, early-phase safety observations in narrow populations. Describing BPC-157 as "proven" for tendon or ligament repair in humans overstates the current evidence; it is more accurate to say the animal signal is consistent enough to justify continued human study, while human efficacy and optimal dosing remain unestablished. Sourcing outside a monitored prescription relationship also carries meaningful quality-control risk, since these products are not subject to the same manufacturing oversight as approved drugs.

TB-500

Thymosin beta-4 has been studied in a genuinely different clinical context, topical treatment of a rare skin fragility disorder, with early-phase results reported for wound closure in that population. That is not the same population or route as the systemic injectable use marketed for musculoskeletal recovery, and no completed randomized trial supports systemic TB-500 for that off-label use. Any specific percentage outcome figures circulating for either peptide should be checked against the primary publication before being repeated as an established number.

Metabolic and body composition peptides

AOD-9604

AOD-9604 is a fragment of human growth hormone that has been studied for lipolytic effects without the glucose or IGF-1 changes associated with full-length GH. A Phase IIb obesity trial did not reach its primary weight-loss endpoint. The FDA has granted it a food-additive (GRAS) designation, which is not a drug approval and does not establish it as an effective weight-loss therapy. Current evidence does not support AOD-9604 as a stand-alone weight-loss treatment.

MOTS-c

MOTS-c is a mitochondria-derived peptide studied in animal models for effects on AMPK activation and insulin sensitivity. Human clinical trial data are limited, and no clinical prescribing guideline currently exists for this peptide. It belongs firmly in the early-research category rather than the clinical-use category.

Sexual health peptides: bremelanotide (PT-141, Vyleesi)

Bremelanotide is a melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, based on randomized trial data showing improved desire scores and reduced associated distress versus placebo. Common side effects include nausea, flushing, and a transient rise in blood pressure lasting several hours after dosing, which is why it is not recommended for people with uncontrolled hypertension or unstable cardiovascular disease. This is an FDA-approved indication in a specific population; extrapolating its use to other populations or for a different intended effect is off-label and outside the trial evidence.

Who should generally avoid these drugs

Contraindications vary by class, but several recur across peptide categories.

Likely to be an absolute contraindication:

• Personal or family history of medullary thyroid carcinoma or MEN-2, for GLP-1 receptor agonists, based on a boxed warning that originates from rodent thyroid C-cell tumor data. Whether this risk translates to humans is still debated in the literature, and this uncertainty should be discussed explicitly rather than glossed over.
• Active or recent malignancy, for growth hormone secretagogues, since IGF-1 elevation is a theoretical driver of tumor proliferation.
• Pregnancy and breastfeeding, for essentially every peptide discussed here, due to insufficient safety data.

Worth a direct conversation with a prescriber rather than self-management:

• History of pancreatitis or gastroparesis, before starting a GLP-1 agent.
• Diabetic retinopathy, before rapid glycemic improvement with a GLP-1 agent.
• Uncontrolled hypertension or cardiovascular disease, before bremelanotide.
• Significant renal impairment, where volume depletion from GI side effects can complicate monitoring.

A decision framework for evaluating any peptide before starting it

Most "which peptide should I take" questions are really three separate questions stacked together: is this indication FDA-approved, is the evidence human or animal, and does a personal contraindication apply. The table below is meant to be used in that order, not skipped to the bottom row.

Exceptions that change the answer: a GLP-1 agent with an FDA-approved indication can still be inappropriate for an individual with gastroparesis or a strong pancreatitis history, even though it clears step 1. Conversely, a compounded peptide with only animal data (BPC-157, for example) may still be a reasonable, physician-supervised choice for a patient who has exhausted standard options and understands the uncertainty, provided steps 3 and 4 are satisfied and expectations are calibrated to the actual evidence tier.

Next step for the reader: if you land in the "animal data only" or "off-label, small trial" row, the useful action is not to search for a stronger claim online but to ask your prescriber directly what specific human data exists for your situation, what monitoring they will use to detect a problem early, and what the plan is if the compound produces no measurable benefit after a defined trial period.

Evidence grade by peptide

What "established" does not mean here: even for approved drugs, established efficacy in a trial population does not guarantee the same magnitude of benefit for every individual patient, and long-term safety data (beyond the trial follow-up period) continues to accumulate after approval.

Monitoring: what a supervised program typically checks

Requirements differ by peptide class, but a reasonable baseline and follow-up pattern includes the following, to be adjusted by the prescribing clinician.

Before starting:

• Comprehensive metabolic panel, complete blood count, HbA1c, fasting lipid panel
• TSH and free T4, particularly before GLP-1 therapy or a GH secretagogue
• IGF-1, before any GH secretagogue
• Blood pressure, resting heart rate, weight
• Eye exam for patients with diabetes before starting a GLP-1 agent, to document baseline retinopathy status

During treatment:

• Early weeks: tolerability, GI symptoms, blood pressure
• Around 3 months: repeat HbA1c and metabolic panel, weight trend
• Around 6 months: full metabolic panel; IGF-1 if on a GH secretagogue, generally kept within the age-adjusted normal range rather than pushed to the upper limit

Guideline bodies including the Endocrine Society have published structured approaches to assessing response to obesity pharmacotherapy at defined intervals and reconsidering the regimen if the expected weight-loss threshold is not met; the exact interval and threshold in the current published guideline should be confirmed directly rather than quoted from memory, since guidelines are updated periodically.

Titration: why speed matters as much as dose

Titrating a GLP-1 agent too fast is a common reason patients stop treatment because of GI side effects; titrating too slowly delays benefit. Standard FDA-labeled titration schedules for semaglutide and tirzepatide start at a low dose and increase at defined intervals (commonly every four weeks) up to a maintenance or maximum dose, with slower titration sometimes used for patients with significant nausea. The exact current label schedule, including dose sizes and interval lengths, should be read directly from the FDA-approved prescribing information rather than reproduced from a secondary summary, since labels are occasionally revised.

Growth hormone secretagogue "protocols" (dose, frequency, cycling pattern) are not standardized by any regulatory body, because these are compounded, off-label products. Any specific regimen circulating online represents one prescriber's or one product's convention, not a proven optimal dose.

Compounded versus FDA-approved peptides: the regulatory picture is unstable

Semaglutide and tirzepatide were both on FDA drug shortage lists at points in the past several years, which under 503A and 503B rules temporarily allowed compounding pharmacies to produce copies. Shortage status has changed over time and can change again; a reader evaluating whether compounded semaglutide or tirzepatide is currently a legal option should check the FDA's current shortage list rather than rely on a fixed date stated in an article, since this status is volatile and time-sensitive. Compounded peptides that have no FDA-approved brand-name comparator at all (BPC-157, ipamorelin, CJC-1295) exist in a different regulatory lane: they can be legally compounded only under a patient-specific prescription from a licensed practitioner, and products sold as "research use only" without a prescription are not a legal or quality-assured route to human use.

What is established, what is plausible, and what is not established

Established: GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide produce clinically meaningful average weight loss and glycemic improvement in randomized trials, and are FDA-approved for defined indications with known, labeled dosing and monitoring requirements. Tesamorelin reduces visceral fat in people with HIV-associated lipodystrophy, its approved indication. Bremelanotide improves desire scores in premenopausal women with hypoactive sexual desire disorder, its approved indication.

Plausible but not established in humans: growth hormone secretagogue combinations (CJC-1295, ipamorelin, sermorelin) likely raise GH and IGF-1 based on early-phase data, but their effect on meaningful outcomes like lean mass or functional strength over the long term has not been established in large controlled trials. BPC-157's tissue-repair signal in animals is consistent enough to justify further study but has not been confirmed as an effective human treatment.

Not established: AOD-9604 as a stand-alone weight-loss agent (failed its primary trial endpoint), TB-500 for systemic musculoskeletal repair (no completed relevant human trial), and MOTS-c for any clinical indication (early animal-stage research only).

Related HealthRX.com guides

• Semaglutide for Weight Loss: Full Clinical Guide
• Tirzepatide vs. Semaglutide: Head-to-Head Comparison
• CJC-1295 and Ipamorelin: Growth Hormone Protocol Guide
• BPC-157: What the Evidence Actually Says
• PT-141 (Bremelanotide) for Sexual Health
• Tesamorelin: FDA-Approved GHRH Analogue